These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 23480583)
21. Progression and treatment of HER2-positive breast cancer. Davoli A; Hocevar BA; Brown TL Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739 [TBL] [Abstract][Full Text] [Related]
22. A Quantitative Assessment of Factors Affecting the Technological Development and Adoption of Companion Diagnostics. Luo D; Smith JA; Meadows NA; Schuh A; Manescu KE; Bure K; Davies B; Horne R; Kope M; DiGiusto DL; Brindley DA Front Genet; 2015; 6():357. PubMed ID: 26858745 [TBL] [Abstract][Full Text] [Related]
23. Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era. Wagner AD; Moehler M Curr Opin Oncol; 2009 Jul; 21(4):381-5. PubMed ID: 19412098 [TBL] [Abstract][Full Text] [Related]
25. [Current situation and challenges in companion diagnostics development]. Nishida M Gan To Kagaku Ryoho; 2014 Dec; 41(13):2529-34. PubMed ID: 25596043 [TBL] [Abstract][Full Text] [Related]
27. [Health care expenditures linked to the use of targeted therapies and diagnostic tests for cancer patients]. Marino P; Bertucci F; Gonçalves A; Seror V Med Sci (Paris); 2012 Mar; 28 Spec No 1():19-23. PubMed ID: 22494652 [TBL] [Abstract][Full Text] [Related]
28. Regulatory considerations for companion diagnostic devices. Lee EY; Shen HC Biomark Med; 2015; 9(1):67-75. PubMed ID: 25605456 [TBL] [Abstract][Full Text] [Related]
29. Impact of genomics on personalized cancer medicine. Arteaga CL; Baselga J Clin Cancer Res; 2012 Feb; 18(3):612-8. PubMed ID: 22298893 [TBL] [Abstract][Full Text] [Related]
32. Beware the Medical-Industrial Complex. Stevens CW; Glatstein E Oncologist; 1996; 1(4):IV-V. PubMed ID: 10388005 [TBL] [Abstract][Full Text] [Related]
33. Cancer Drug Development: New Targets for Cancer Treatment. Curt GA Oncologist; 1996; 1(3):II-III. PubMed ID: 10387987 [TBL] [Abstract][Full Text] [Related]
34. Clinical trials of vaccines for immunotherapy in pancreatic cancer. Plate J Expert Rev Vaccines; 2011 Jun; 10(6):825-36. PubMed ID: 21692703 [TBL] [Abstract][Full Text] [Related]
35. Health-related quality of life in early breast cancer. Groenvold M Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024 [TBL] [Abstract][Full Text] [Related]
36. Biomarkers of Resistance to Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer. Banck MS; Grothey A Clin Cancer Res; 2009 Dec; 15(24):7492-7501. PubMed ID: 20008849 [TBL] [Abstract][Full Text] [Related]
37. Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents. Le Tourneau C; Vidal L; Siu LL Drug Resist Updat; 2008 Jun; 11(3):99-109. PubMed ID: 18515176 [TBL] [Abstract][Full Text] [Related]
38. Complementary versus companion diagnostics: apples and oranges? Milne CP; Bryan C; Garafalo S; McKiernan M Biomark Med; 2015; 9(1):25-34. PubMed ID: 25605453 [TBL] [Abstract][Full Text] [Related]
39. Targeted therapies with companion diagnostics in the management of breast cancer: current perspectives. Myers MB Pharmgenomics Pers Med; 2016; 9():7-16. PubMed ID: 26858530 [TBL] [Abstract][Full Text] [Related]
40. The Regulation of Companion Diagnostics: A Global Perspective. Ansari M Ther Innov Regul Sci; 2013 Jul; 47(4):405-415. PubMed ID: 30235516 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]